Inclusion Criteria:~* CT or MRI since disease onset excluding structural lesions sufficient to account for the
participant's dementia~* Mini-Mental State Exam (MMSE) score between 12 and 26, inclusively~* Clinical Dementia
Rating (CDR) score of 1 or 2 (mild to moderate AD severity) at both screening and baseline~* Women must be
2-years post-menopausal or surgically sterile.~* Generally healthy and ambulatory or ambulatory-aided (i.e.,
walker or cane); vision and hearing (hearing aid permissible) sufficient for compliance with testing
procedures~* Concomitant medications: Participants may be on stable doses of cholinesterase inhibitors for 90
days prior to screening (may not be started during the trial); antidepressant or antipsychotic medications are
acceptable if symptoms are controlled and therapy is at stable dosage for at least 30 days prior to screening;
vitamin E at 200 IU daily will be provided to all participants beginning at baseline/randomization (higher
doses must be discontinued at the screening visit)~
